People with type 2 diabetes have three to four times the risk of developing liver cancer, and more than twice the risk of developing pancreatic cancer than non-diabetic individuals.

A breakthrough may have been made for the treatment, diagnosis and prevention of Type Two diabetes.

The first test in humans offers hope of the device’s potential to save the lives of people with acute renal failure, researchers at the University of Michigan Health System report.

Eating white bread with each meal increased the risk for diabetes more than 30 percent. Fans of white bread, hear this: it increases your risk of type 2 diabetes, the most common form of the illness, new research shows.

“Diabetic patients with end stage renal disease will usually die within 4 years, so probably it’s too late in the vascular life of the patient to [start] statin treatment.”

In subjects with type 2 diabetes and hypertension but with normoalbuminuria, the use of trandolapril plus verapamil and trandolapril alone decreased the incidence of microalbuminuria.

Most patients with Type 2 diabetes are not receiving care as per the ADA guidelines released in 2004 for diabetic nephropathy.

A landmark study conducted by the National Institutes of Health (NIH) found that those at risk for type-II diabetes could reduce the likelihood of developing the disease by 58 percent through 30 minutes of moderate daily exercise.

The oral anti-diabetic thiazolidinediones (TZDs), such as rosiglitazone and pioglitazone could offer a valuable complement to conventional chemotherapy for pancreatic cancer.

People with type 2 diabetes who have progressed to kidney failure don’t gain much benefit from treatment with a statin drug like Lipitor.